Moderna stock surges 131% on Phase 3 cancer-vaccine trial win
Moderna stock jumped A Phase 3 win against the standard of care sent the biotech's shares up 131% and left short sellers down $4.8 billion.
following positive Phase 3 results for its cancer vaccine, which outperformed standard-of-care treatment in the trial.
The surge cost short sellers A Phase 3 win against the standard of care sent the biotech's shares up 131% and left short sellers down $4.8 billion.
in losses, according to Decrypt.
Sources: MarketWatch, Decrypt
This article is for information only and is not financial advice.
What the market did
Each figure is this site’s own reading, with what it was measured against. A blank is a reading nobody took, not a zero. The before-the-headline window prints the rate a RANDOM hour clears the same bar, because a hit rate without its null is not a finding.
Cite this
Archived copy · an independent capture of this page at the Internet Archive, kept so this report can be checked against what it said on the day
← more bytes